What's Next For Amarin Investors?
It's been an emotional and financial rollercoaster for Amarin (AMRN), with the hype surrounding Vascepa leaving investors deep underwater, gasping for air.
Since attaining FDA approval for its lead product on July 26 last year, shares began and continued to tumble, with the negative FDA advisory committee panel meeting dealing a near coup de grace to the proverbial Pequod. Consequently, Amarin's high-profile failure has served to largely sour investors on companies with fish-oil or similar products. Enter Neptune Technologies & Bioresources (NEPT), a similar company that is significantly de-risked and poised for double to triple digit returns over the next year.
Unless otherwise noted, financial statistics...
Only subscribers can access this article, which is part of the PRO research library covering 3,584 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: